7-Monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1337-1341

  Van Acker, Frédérique A A ^a,b,d   Van Acker, Saskia A B E ^a,b   Kramer, Klaas ^b   Haenen, Guido R M M ^c   Bast, Aalt ^c   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MONOXERUTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FLAVONOIDS; HEART; HYDROXYETHYLRUTOSIDE; MALE; MICE; MICE, INBRED BALB C; MYOCARDIUM; WEIGHT GAIN;

EID: 0034051684     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., and Young, R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (Washington DC), 197: 165-167, 1977.
2. Green, M. D., Alderton, P., Gross, J., Muggia, F. M., and Speyer, J. L. Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529). Pharmacol. Ther., 48: 61-69, 1990.
3. Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., and Joenje, H. Doxorubicin (Adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther., 47: 219-231, 1990.
4. Takács, I. E., Matkovics, B., Varga, S. I., Homolay, P., Fehér, G., and Seres, T. Study of the myocardial antioxidant defense in various species. Pharmacol. Res., 25: 177-178, 1992.
5. 2, but also by potentiating the catalytic activity of ferrous ions. Toxicol. Lett. (Amst.), 22: 153-159, 1984.
6. Myers, C. The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol., 25: 10-14, 1998.
7. Sparano, J. A. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin. Oncol., 25: 66-71, 1998.
8. Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V., Hochster, H., and Meyers, M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10: 117-127, 1992.
9. Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spieer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., Speyer, J., Mittelman, A., Reddy, S., Pendergrass, K., Velez-Garcia, E., Ewer, M. S., Bianchine, J. R., and Gams, R. A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol., 15: 1318-1332, 1997.
10. Venturini, M., Michelotti, A., Del Mastro, L., Gallo, L., Carnino, F., Garrone, O., Tibaldi, C., Molea, N., Bellina, R. C., Pronzato, P., Cyrus, P., Vinke, J., Testore, F., Guelfi, M., Lionetto, R., Bruzzi, P., Conte, P. F., and Rosso, R. Multicenter randomized controlled clinical trial to evaluate Cardioprotection of dexrazoxane versus no Cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol., 14: 3112-3120, 1996.
11. Kolaric, K., Bradamante, V., Cervek, J., Cieslinska, A., Cisarz-Filipcak, E., Denisov, L. E., Donat, D., Drosik, K., Gershanovic, M., Hudziec, P., Jelic, S., Jurga, L., Kalasiewicz, M., Kowgird, L., Kozacka, M., Lichinitzer, M., Machalski, M., Mechl, Z., and Odintsov, S., Powlicki, M., Rubach, D., Roth, A., Stabue, B., Tomczak, J., Utracka, B., Zborzi, J., and Rogan, J. A Phase II trial of Cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology (Basel), 52: 251-255, 1995.
12. Lopez, M., and Vici, P. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity. Semin. Oncol., 25 (Suppl. 10): 55-60, 1998.
13. Havsteen, B. Flavonoids: a class of natural products of high pharmacological potency. Biochem. Pharmacol., 32: 1141-1148, 1983.
14. Rekka, E., and Kourounakis, P. N. Effect of hydroxyethyl rutosides and related compounds on lipid peroxidation and free radical scavenging activity. Some structural aspects. J. Pharm. Pharmacol., 43: 486-491, 1991.
15. van Acker, S. A. B. E., Tromp. M. N. J. L., Haenen, G. R. M. M., van der Vijgh, W. J. F., and Bast, A. Flavonoids as scavengers of nitric oxide radical. Biochem. Biophys. Res. Commun., 214: 755-759, 1995.
16. van Acker, S. A. B. E., van den Berg, D-J., Tromp, M. N. J. L., Griffioen, D. H., van Bennekom, W. P., van der Vijgh, W. J. F., and Bast, A. Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med., 20: 331-342, 1996.
17. Rice-Evans, C. A., Miller, N. J., and Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med., 20: 933-956, 1996.
18. Leuschner, F., Leuschner, A., Schwerdtfeger, W., and Dontenwill, W. 12-Monate-toxizitaet eines gemisches von hydroxyaethylrutosiden HR/NdF, charge 1060 an maeusen bei peroraler applikation. Laboratorium fuer Pharmakologie und Toxikologie, Hamburg, Germany: 1973.
19. van Acker, S. A. B. E., Kramer, K., Grimbergen, J. A., van den Berg, D-J., van der Vijgh, W. J. F., and Bast, A. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. Br. J. Pharmacol., 115: 1260-1264, 1995.
20. Kramer, K., Van Acker, S. A. B. E., Voss, H. P., Grimbergen, J. A., Van der Vijgh, W. J. F., and Bast, A. Use of telemetry to record electrocardiogram and heart rate in freely moving mice. J. Pharmacol. Toxicol. Methods, 30: 209-215, 1993.
21. Kramer, K., Van Acker, S. A. B. E., Grimbergen, J. A., Van der Vijgh, W. J. F., and Bast, A. Telemetrie, een nieuwe en nauwkeurige methode voor cardiovasculaire metingen in vrij bewegende muizen. Biotechniek, 33: 117-119, 1994.
22. Van Acker, S. A. B. E., Kramer, K., Voest, E. E., Grimbergen, J. A., Zhang, J., Van der Vijgh, W. J. F., and Bast, A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A model to test potential protectors. Cancer Chemother. Pharmacol., 38: 95-101, 1996.
23. Postan, M., Bailey, J. J., Dvorak, J. A., McDaniel, J. P., and Pottala, E. W. Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection. Am. J. Trop. Med. Hyg., 37: 541-549, 1987.
24. Monath, T. P., Kemp, G. E., Cropp, C. B., and Chandler, F. W. Necrotizing myocarditis in mice infected with western equine encephalitis virus: clinical, electrocardiographic, and histopathologic correlations. J. Infect. Dis., 138: 59-66, 1978.
25. van Acker, S. A. B. E., Boven, E., Kuiper, K., van den Berg, D-J., Grimbergen, J. A., Kramer, K., Bast, A., and van der Vijgh, W. J. F. Monohydroxyethylrutoside is a dose-dependent cardioprotective agent and does not affect the antitumour activity of doxorubicin. Clin. Cancer Res., 3: 1747-1754, 1997.
26. Olson, R. D., and Mushlin, P. S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J., 4: 3076-3086, 1990.
27. Powis, G. Anthracycline metabolism and free radical formation. In: G. Powis and R. A. Prough (eds.), Metabolism and Action of Anti-Cancer Drugs, pp. 211-260. London: Taylor & Francis Ltd., 1987.
28. Allen, A. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol., 19: 529-542, 1992.
29. Goebel. M., and Kaplan, E. Anthracycline-induced cardiotoxicity: a review. Onkologie, 15: 198-204, 1992.
30. Myers, C., Bonow, R., Palmeri, S., Jenkins, J., Cordon, B., Locker, G., Doroshaw, J., and Epstein, S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteïne. Semin. Oncol., 10: 53-55, 1991.
31. Herman, E. H., and Ferrans, V. J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Investig., 49: 69-77, 1983.
32. Pritsos, C. A., Sokoloff, M., and Gustafson, D. L. PZ-51 (Ebselen) In vivo protection against Adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. Biochem. Pharmacol., 44: 839-841, 1992.
33. Breed, J. G., Zimmerman, A. N., Dormans, J. A., and Pinedo, H. M. Failure of the antioxidant vitamin E to protect against Adriamycin-induced cardiotoxicity in the rabbit. Cancer Res., 40: 2033-2038, 1980.
34. Legha, S. S., Wang, Y. M., Mackay, B., Ewer, M., Hortobagyi, G. N., Benjamin, R. S., and Ali, M. K. Clinical and pharmacologic investigation of the effects of α-tocopherol and Adriamycin cardiotoxicity. Ann. N. Y. Acad. Sci., 393: 411-418, 1982.
35. van Vleet, J. F., Ferrans, V. J., and Weirich, W. E. Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol., 99: 13-42, 1980.
36. Koning, J., Palmer, P., Franks, C. R., Mulder, D. E., Speyer, J. L., Green, M. D., and Hellmann, K. Cardioxane-ICRF-187 towards anti-cancer drug specificity through selective toxicity reduction. Cancer Treat. Rev., 18: 1-19, 1991.
37. Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jaquotte, A., Wernz, J., Feit, F., Slater, W., Blum, R., and Muggia, F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med., 319: 745-752, 1988.
38. Von Hoff, D. D. Phase I trials of dexrazoxane and other potential applications for the agent. Semin. Oncol., 25: 31-36, 1998.
39. Van der Vijgh, W. J. F., Maessen, P. A., and Pinedo, H. M. Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother. Pharmacol., 26: 9-12, 1990.
40. Hackett, A. M., and Griffiths, L. A. The disposition and metabolism of 3′,4′,7-tri-O-(β-hydroxyethyl)rutoside and 7-mono-O-(β-hydroxyethyl)rutoside in the mouse. Xenobiotica, 7: 641-651, 1977.
41. Shapira, J., Gotfried, M., Lishner, M., and Ravid, M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer (Phila.), 65: 870-873, 1990.
42. Lieverse, R. J., and Ossenkoppele, G. J. Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature. Neth. J. Med., 38: 33-34, 1991.
43. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S. L., Blumenschein, G. R., and Freireich, E. J. Reduction of doxorubicin cardioloxicity by prolonged continuous intravenous infusion. Ann. Intern. Med., 96: 133-139, 1982.